According to filings with the U.S. Securities and Exchange Commission, ViyaMD is raising up to $5 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About ViyaMD
ViyaMD is a clinical intelligence company that builds infrastructure to make physician-level medical understanding accessible at scale for organizations that need to navigate complex medical information. Through a proprietary clinical intelligence platform forged from the combined expertise of leaders in medicine, law, and technology, ViyaMD transforms scarce specialist knowledge into scalable technology that can deliver expert-level medical reasoning across diverse workflows. Its solutions support healthcare providers in delivering care, attorneys in building medically complex legal cases, and insurers in assessing clinical risk, enabling each to access and apply rigorously validated medical knowledge wherever it is needed. ViyaMD emphasizes augmenting, not replacing, human expertise by providing AI-powered tools that streamline workflows, extend clinicians reach, and keep the focus on patient care, diagnosis, and treatment rather than on technological burdens. By redefining how existing systems use clinical data, the company positions technology as a foundation for innovation in healthcare, turning medical complexity into an asset and making clinical intelligence universally accessible.

To learn more, visit https://www.viyamd.com/
LinkedIn: https://www.linkedin.com/company/viyamd/

Contact:
Josh Grischkan, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.